Table 4.
Subgroup and meta-regression analysis of nodal detection rate
| Subgroup analysis | Meta-regression analysis | |||
|---|---|---|---|---|
| Risk ratio | P | Coefficient b | P | |
| Probe | 0.3566 (0.1641, 0.5490)* | <0.001 | ||
| ȃSentimag® | 1.072 (1.038, 1.108) | <0.001 | ||
| ȃTokyo probe | 1.456 (1.318, 1.608) | <0.001 | ||
| SPIO | −0.0019 (−0.1593, 0.1555) | 0.981 | ||
| ȃFerucarbutran | 1.456 (1.318, 1.608) | <0.001 | ||
| ȃMagtrace® | 1.066 (1.010, 1.126) | 0.021 | ||
| ȃSienna+® | 1.078 (1.032, 1.126) | 0.001 | ||
| Injection site | 0.0395 (−0.1173, 0.1963) | 0.622 | ||
| ȃPeritumoral | 1.303 (1.008, 1.683) | 0.043 | ||
| ȃSubareolar | 1.082 (1.043, 1.122) | <0.001 | ||
| Timing of injection | 0.1473 (0.0371, 0.2574)† | 0.009 | ||
| ȃPreoperative | 1.284 (1.095, 1.507) | 0.002 | ||
| ȃPeroperative | 1.070 (1.033, 1.109) | <0.001 | ||
| Setting | −0.1179 (−0.2231, −0.0127)‡ | 0.028 | ||
| ȃUpfront | 1.078 (1.039, 1.118) | <0.001 | ||
| ȃAfter neoadjuvant therapy | 1.308 (0.894, 1.912) | 0.167 | ||
| Comparison | −0.1258 (−0.2685, 0.0169) | 0.084 | ||
| ȃPaired | 1.097 (1.057, 1.139) | <0.001 | ||
| ȃUnpaired | 0.930 (0.841, 1.029) | 0.158 | ||
| Subgroup | −0.8075 (–1.2011, –0.4139)§ | <0.001 | ||
| ȃStandard SLNB | 1.080 (1.044, 1.118) | <0.001 | ||
| ȃDelayed SLNB | 2.571 (1.788, 3.699) | <0.001 | ||
| Injection volume (ml) | 0.0092 (–0.0365, 0.05489) | 0.693 | ||
| ȃ0.5 | 1.188 (0.796, 1.772) | 0.400 | ||
| ȃ1.0 | 1.128 (1.053, 1.207) | 0.001 | ||
| ȃ1.5 | 1.001 (0.926, 1.083) | 0.970 | ||
| ȃ2.0 | 1.175 (1.025, 1.346) | 0.021 | ||
| ȃ5.0 | 1.069 (1.031, 1.110) | <0.001 | ||
Values in parentheses are 95% confidence intervals. Coefficient for *Tokyo probe, †preoperative injection, ‡upfront surgery or §standard sentinel lymph node biopsy. SPIO, superparamagnetic iron oxide nanoparticles; SLNB, sentinel lymph node biopsy.